Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
10
×
boston top stories
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
biotech
crispr
gene editing
national
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
glaxosmithkline
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
crispr therapeutics
crispr-cas9
deals
editas medicine
fda
indiana blog main
indiana top stories
startups
biogen
boston
clinical trials
eli lilly
What
crispr
10
×
bio
roundup
cas
editing
gene
medicine
ceo
editas
new
today
big
cancer
human
katrine
known
million
scientists
therapeutics
years
acquisitions
albert
allergan
alliance
allogene
available
based
beam
biggest
biopharma
biosciences
blessing
bosley
bosley's
bosley’s
bourla
bridge
bristol
bucks
buy
Language
unset
unknown
Current search:
" boston blog main "
×
crispr
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M